Taizhou
Regions
Industrial Parks
中文
Home > Highlights

Pharma giant AstraZeneca expands Taizhou base

LMS
etaizhou.gov.cn|Updated: August 21, 2023

6295623793554204100.jpeg

A panoramic view of China Medical City. [Photo/WeChat account: weigg6666]

Pharmaceutical giant AstraZeneca signed a memorandum of cooperation with China Medical City – located in Taizhou city of East China's Jiangsu province – on Aug 16, to further bolster the high-quality development of China's pharmaceutical industry.

With an investment of about $300 million, AstraZeneca's Taizhou production base was put into use in 2014. Last year, the company announced the establishment of a new production line in Taizhou, which will be completed and put into operation this year.

The new line plans to achieve an annual production capacity of over 2 billion units of medicine and an annual output value of over 10 billion yuan ($1.37 billion).

Through this expanded capacity, AstraZeneca wants to see its Taizhou base become a global production center to bring innovative achievements to more patients.

"We hope to help the Chinese medical industry improve its quality and efficiency in the future, and unleash the advantages and potential of the industry," said Wang Lei, director general of AstraZeneca in China.

More Stories

Regions
Industrial Parks
Bureaus
Others
Copyright ©  Taizhou Medical High Tech Zone, Taizhou City.
All Rights Reserved.
Presented by China Daily.